Обзор современных рекомендаций ведения женщин с выделениями из половых путей

1. Роговская С.И., Липова Е.В., ред. Шейка матки, влагалище, вульва. Физиология, патология, кольпоскопия, эстетическая коррекция. Руководство для практикующих врачей. М.: StatusPraesens; 2014: 34-43.
2. Klebanoff M.A., Nansel T.R., Brotman R.M., Zhang J., Yu K.F., Schwebke J.R., Andrews W.W. Personal hygienic behaviors and bacterial vaginosis. Sex. Transm. Dis. 2010; 37(2): 94-9.
3. Workowski K.A., Bolan G.A., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2015; 64(3): 69-72.
4. Sherrard J., Wilson J., Donders G., Mendling W., Jensen J.S. European (IUSTI/WHO) Guideline on the management of vaginal discharge. Int. J. STD AIDS. 2018; 29(13): 1258-72.
5. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: Российское общество акушеров-гинекологов; 2019. 56 с.
6. Donders G.G., Ruban K., Bellen G. Selecting anti-microbial treatment of aerobic vaginitis. Curr. Infect. Dis. Rep. 2015; 17(5): 477.
7. Donders G.G., Zodzika J., Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin. Pharmacother. 2014; 15(5): 645-57.
8. Verstraelen H., Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr. Opin. Infect. Dis. 2013; 26: 86-9.
9. Kelly C.G., Younson J.S. Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces. Expert Opin. Investig. Drugs. 2009; 9(8): 1711-21.
10. Asadi A., Razavi S., Talebi M., Gholami M. A review on anti-adhesion therapies of bacterial diseases. Infection. 2019; 47: 25-6.
11. Van Dijk W. Further characterization of negatively charged polysaccharides isolated from concentrated Aloe vera gel with regard to antibacterial properties and molecular structure. Phytomedicine. 2006; 16(9): 856-63.Dermatological report on human patch test with 2QR-complex (batch 2011002374). World J. Gastroenterol. 2012; 18: 2026-34.
12. Eurofins. Cytotoxicity-Direct contact on 2QR-complex 0.8 mg/g report 2012/545-1. Curr. Med. Chem. 2012; 17: 129-38.
13. Bojovic T., Bojovic D., Boyer de La Tour F.-X., Lamers B. First line treatment and relief of bacterial vaginosis-related vaginal complaints with metronidazole and Multi-Gyn® ActiGel. Eur. Obstet. Gynaecol. 2012; 7(2): 103-6.
14. Балан В.Е., Тихомирова Е.В., Овчинникова В.В. Рецидивирующий бактериальный вагиноз – возможность увеличения продолжительности ремиссии. Акушерство и гинекология. 2017; 1: 83-8.
15. Dols J.A.M., Boon M.E. An in vitro study of the effects of self care Gels on desirable and undesirable vaginal microbiota. Eur. Obstet. Gynaecol. 2012; 7(2): 107-10.
16. Palacios S., Nappi R.E., Bruyniks N., Particco M., Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018; 21(3): 286-91.Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. J. Front. Microbiol. 2019; 10: Article 193.
17. Mason M.J., Winter A.J. How to diagnose and treat aerobic and desquamative inflammatory vaginitis. Sex. Transm. Infect. 2017; 93: 8-10.
18. Bruyniks N., Biglia N., Palacios S., Mueck A.O. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017; 20(3): 195-204.
19. Gaspar A., Brandi H., Gomez V., Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg. Med. 2017; 49(2): 160-8.
20. Gambacciani M., Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017; 99: 10-5.
21. Балан В.Е. Урогенитальные расстройства в климактерии (клиника, диагностика, заместительная гормонотерапия): дисс. … д-ра мед. наук. М.; 295 с.
22. Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climateric. 2016; 19(2): 151-61.
23. Chatsiproios D., Schmidts-Winkler I.M., König L., Masur C., Abels C. Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment – An open prospective multicenter study. PLoS One. 2019; 14(1): e0210967.
24. Kim Y.H., Park S., Lee M., Hahn S., Jeon M.J. Effect of a pH-balanced vaginal gel on dyspareunia and sexual function in breast cancer survivors who were premenopausal at diagnosis: a randomized controlled trial. Obstet. Gynecol. 2017; 129(5): 870-6.
25. Vermani K., Garg S., Zaneveld L.J. Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment. Drug Dev. Ind. Pharm. 2002; 28(9): 1133-46.

Поступила 12.04.2019

Принята в печать 19.04.2019